Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.
Latest from Jessica Merrill
CEO Bill Meury and president-R&D Pablo Cagnoni outlined the path to reduce Incyte’s reliance on the blockbuster Jakafi as it heads towards loss of exclusivity in 2028/2029.
Management said it sees big potential for obesity drugs as cash-pay medications in the global market, while reporting Q4 financial results.
Companies like argenx, Insmed and Madrigal are executing successfully in the commercial market and attracting investor attention. Their success could pave the way for more.
The company is getting ready for multiple cancer drug launches, potentially including anti-PD-L1/VEGF pumitamig. Chief commercial officer Annemarie Hanekamp spoke to Scrip.
The company’s chief operating officer and next CEO Karen Massey talked with Scrip about the rise of Vyvgart and how the Dutch biotech is planning for the next phase of growth.
Scrip senior editor Jessica Merrill, Scrip US managing editor Mandy Jackson and In Vivo senior reporter David Wild discuss trends and topics from interviews and presentations at the J.P. Morgan Healthcare Conference and Biotech Showcase.